| abstract |
The present invention relates to amides having activity as S1P receptor modulators and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds include, for example, autoimmune diseases and related immune abnormalities (including systemic lupus erythematosus), inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis To treat and prevent rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granulomas; and to treat other conditions In addition, it can be used as an immunomodulator. |